A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

• Asahina H.

• Yamazaki K.

• Kinoshita I.

• Sukoh N.

• Harada M.

• Yokouchi H.

• Ishida T.

• Ogura S.

• Kojima T.

• Okamoto Y.

• Fujita Y.

• Dosaka-akita H.

• Isobe H.

• Nishimura M.

Journal

• British Journal of Cancer

  British Journal of Cancer 95 (8), 998-1004, 2006-10-23

  Nature Publishing Group

Keywords

• gefitinib
• non-small cell lung cancer (NSCLC)
• epidermal growth factor receptor (EGFR)
• mutation
• first-line therapy

Details

• CRID: 1570291227561181440
• NII Article ID: 120000969217
• ISSN: 00070920
• Web Site: http://hdl.handle.net/2115/21810
• Text Lang: en
• Data Source:
  • CiNii Articles